FDA grants Abiomed breakthrough device designation for expandable heart pump

Danvers, Mass.-based medical device company Abiomed received the FDA’s breakthrough device designation for its Impella ECP heart pump.

Advertisement

The designation means the FDA will prioritize the device’s regulatory review processes, according to an Aug. 18 news release.

According to Abiomed, the Impella ECP pump is the world’s smallest heart pump that expands inside the body to support the heart’s blood flow.

Abiomed was granted the designation after reporting positive clinical data from a study of 21 patients treated with the heart pump.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Cardiology

  • Cardiology is expanding increasingly into ASCs as CMS policy updates, advancements in cardiovascular innovation and population health concerns necessitate more…

  • As more cardiac procedures move into the ambulatory setting, developers are taking different approaches to what that shift should look…

Advertisement

Comments are closed.